MA43302A - Polypeptides inhibant le ligand cd40l - Google Patents
Polypeptides inhibant le ligand cd40lInfo
- Publication number
- MA43302A MA43302A MA043302A MA43302A MA43302A MA 43302 A MA43302 A MA 43302A MA 043302 A MA043302 A MA 043302A MA 43302 A MA43302 A MA 43302A MA 43302 A MA43302 A MA 43302A
- Authority
- MA
- Morocco
- Prior art keywords
- polypeptides
- inhibited
- ligand cd40l
- cd40l
- ligand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562260411P | 2015-11-27 | 2015-11-27 | |
US201662345967P | 2016-06-06 | 2016-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43302A true MA43302A (fr) | 2021-03-17 |
Family
ID=57471837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043302A MA43302A (fr) | 2015-11-27 | 2016-11-28 | Polypeptides inhibant le ligand cd40l |
Country Status (22)
Country | Link |
---|---|
US (1) | US11248055B2 (fr) |
EP (2) | EP3932945A1 (fr) |
JP (1) | JP7256011B2 (fr) |
KR (1) | KR20180080337A (fr) |
CN (1) | CN108473561B (fr) |
AU (1) | AU2016360987A1 (fr) |
BR (1) | BR112018010802A2 (fr) |
CA (1) | CA3006398A1 (fr) |
CL (1) | CL2018001400A1 (fr) |
CO (1) | CO2018005921A2 (fr) |
DO (1) | DOP2018000128A (fr) |
EC (1) | ECSP18046820A (fr) |
GT (1) | GT201800102A (fr) |
IL (1) | IL259249A (fr) |
MA (1) | MA43302A (fr) |
MX (1) | MX2018006377A (fr) |
PE (1) | PE20181956A1 (fr) |
PH (1) | PH12018501114A1 (fr) |
RU (1) | RU2018122255A (fr) |
SG (2) | SG11201803976VA (fr) |
TN (1) | TN2018000180A1 (fr) |
WO (1) | WO2017089618A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018104444A1 (fr) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Domaines variables uniques d'immunoglobuline se liant à l'albumine sérique améliorée |
KR20230165374A (ko) | 2017-01-17 | 2023-12-05 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
SG10202108972RA (en) | 2017-01-17 | 2021-09-29 | Ablynx Nv | Improved serum albumin binders |
SG11202004144VA (en) * | 2017-11-17 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against pd-l1 |
CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
WO1994025591A1 (fr) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION D'ANTICORPS OU DE FRAGMENTS FONCTIONNALISES D'ANTICORPS, DERIVES DES IMMUNOGLOBULINES A CHAINE LOURDE DE $i(CAMELIDAE) |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
EP0739981A1 (fr) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire |
EP0937140B1 (fr) | 1996-06-27 | 2007-09-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Anticorps ayant une interaction spécifique avec le site actif ou la fissure d'une molécule cible |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
ATE461282T1 (de) | 1997-10-27 | 2010-04-15 | Bac Ip Bv | Multivalente antigenbindende proteine |
BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
CA2321199A1 (fr) | 1998-02-19 | 1999-08-26 | William A. Brady | Compositions et procedes de regulation de l'activation des lymphocytes |
EP0967284A1 (fr) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiestérases |
AU3041100A (en) | 1999-01-05 | 2000-07-24 | Unilever Plc | Binding of antibody fragments to solid supports |
DE60013767T3 (de) | 1999-01-19 | 2009-07-09 | Unilever N.V. | Verfahren zur herstellung von antikörperfragmenten |
WO2000046383A2 (fr) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Methode de modulation de la biosynthese de metabolite dans des cellules recombinees |
DE1100895T1 (de) | 1999-03-15 | 2001-09-06 | Univ British Columbia | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts |
CN100434441C (zh) | 1999-04-22 | 2008-11-19 | 荷兰联合利华有限公司 | 利用单价抗原-结合蛋白抑制病毒感染 |
KR100476519B1 (ko) | 1999-06-18 | 2005-03-17 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Atp 결합 카세트 트랜스포터 단백질 abc1을사용하여 콜레스테롤 유출을 증가시키고 hdl을상승시키기 위한 조성물 및 방법 |
AU6322900A (en) | 1999-08-02 | 2001-02-19 | Keygene N.V. | Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
EP1233987B1 (fr) | 1999-11-29 | 2009-08-19 | Bac Ip B.V. | Immobilisation de molecules de liaison d'antigene a domaine unique |
WO2001040310A2 (fr) | 1999-11-29 | 2001-06-07 | Unilever Plc | Immobilisation de proteines |
ATE422369T1 (de) | 1999-12-24 | 2009-02-15 | Genentech Inc | Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen |
ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
WO2001090190A2 (fr) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Fragments d'anticorps de fixation d'antigenes monodomaines, derives d'anticorps de lamas |
DK1360207T3 (da) | 2000-12-13 | 2011-09-05 | Bac Ip B V | Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler |
JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
WO2003050531A2 (fr) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes |
EP1456237A2 (fr) | 2001-12-21 | 2004-09-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Procede de clonage de sequences de domaines variables |
WO2003055527A2 (fr) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Nouveaux immunoconjugues utiles pour le traitement de tumeurs |
US7521543B2 (en) | 2002-10-23 | 2009-04-21 | Ludwig Institute For Cancer Research | A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same |
AU2003286004A1 (en) | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
EP2336179A1 (fr) | 2002-11-08 | 2011-06-22 | Ablynx N.V. | Anticorps a domaine unique stabilises |
US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
AU2004204262B2 (en) | 2003-01-10 | 2010-11-04 | Ablynx N.V. | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
KR20070084170A (ko) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
EP1844073A1 (fr) | 2005-01-31 | 2007-10-17 | Ablynx N.V. | Procede de generation de sequences a domaine variable d'anticorps a chaine lourde |
CA2962819C (fr) | 2005-05-18 | 2021-07-27 | Ablynx Nv | Nanocorps ameliores utilises contre la serum albumine humaine |
NZ563392A (en) | 2005-05-20 | 2009-12-24 | Ablynx Nv | Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders |
JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
AU2007328900A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
AU2008219216A1 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
CN103214577B (zh) | 2007-03-22 | 2015-09-02 | 生物基因Ma公司 | 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途 |
NZ581097A (en) | 2007-05-24 | 2012-03-30 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
US8217140B2 (en) | 2008-04-17 | 2012-07-10 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
CN102112494A (zh) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
US8962807B2 (en) * | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
EP2654792A4 (fr) * | 2010-12-22 | 2016-05-11 | Abbvie Inc | Protéines de liaison à une demi-immunoglobuline et leurs utilisations |
US20180009888A9 (en) | 2011-06-23 | 2018-01-11 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
EP4218933A1 (fr) | 2011-06-23 | 2023-08-02 | Ablynx NV | Proteines se liant a l'albumine serique |
UY34254A (es) | 2011-08-17 | 2013-04-05 | Glaxo Group Ltd | Proteínas y péptidos modificados. |
ES2769806T3 (es) | 2011-10-13 | 2020-06-29 | Bristol Myers Squibb Co | Polipéptidos de anticuerpo que antagonizan al CD40L |
ES2779123T3 (es) | 2013-09-26 | 2020-08-13 | Ablynx Nv | Nanobodies biespecíficos |
CA2943177A1 (fr) * | 2014-03-19 | 2015-09-24 | Bristol-Myers Squibb Company | Procedes de traitement du rejet d'une transplantation par utilisation d'un anticorps a domaine unique dirige contre cd40l |
IL256800B2 (en) | 2015-07-14 | 2023-04-01 | Immunext Inc | An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy |
US10669343B2 (en) | 2015-08-05 | 2020-06-02 | Janssen Biotech, Inc. | Anti-CD154 antibodies and methods of using them |
-
2016
- 2016-11-28 KR KR1020187018169A patent/KR20180080337A/ko not_active Application Discontinuation
- 2016-11-28 WO PCT/EP2016/079048 patent/WO2017089618A1/fr active Application Filing
- 2016-11-28 EP EP21179221.3A patent/EP3932945A1/fr active Pending
- 2016-11-28 SG SG11201803976VA patent/SG11201803976VA/en unknown
- 2016-11-28 RU RU2018122255A patent/RU2018122255A/ru unknown
- 2016-11-28 JP JP2018527745A patent/JP7256011B2/ja active Active
- 2016-11-28 CN CN201680068704.XA patent/CN108473561B/zh active Active
- 2016-11-28 EP EP16805359.3A patent/EP3380517B1/fr active Active
- 2016-11-28 MA MA043302A patent/MA43302A/fr unknown
- 2016-11-28 AU AU2016360987A patent/AU2016360987A1/en not_active Abandoned
- 2016-11-28 TN TNP/2018/000180A patent/TN2018000180A1/en unknown
- 2016-11-28 CA CA3006398A patent/CA3006398A1/fr not_active Abandoned
- 2016-11-28 US US15/778,677 patent/US11248055B2/en active Active
- 2016-11-28 BR BR112018010802A patent/BR112018010802A2/pt not_active Application Discontinuation
- 2016-11-28 PE PE2018001013A patent/PE20181956A1/es unknown
- 2016-11-28 MX MX2018006377A patent/MX2018006377A/es unknown
- 2016-11-28 SG SG10201913503VA patent/SG10201913503VA/en unknown
-
2018
- 2018-05-09 IL IL259249A patent/IL259249A/en unknown
- 2018-05-21 GT GT201800102A patent/GT201800102A/es unknown
- 2018-05-22 DO DO2018000128A patent/DOP2018000128A/es unknown
- 2018-05-24 CL CL2018001400A patent/CL2018001400A1/es unknown
- 2018-05-25 PH PH12018501114A patent/PH12018501114A1/en unknown
- 2018-06-08 CO CONC2018/0005921A patent/CO2018005921A2/es unknown
- 2018-06-21 EC ECSENADI201846820A patent/ECSP18046820A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017089618A1 (fr) | 2017-06-01 |
JP2019504822A (ja) | 2019-02-21 |
GT201800102A (es) | 2019-08-15 |
EP3932945A1 (fr) | 2022-01-05 |
US20180355050A1 (en) | 2018-12-13 |
ECSP18046820A (es) | 2018-07-31 |
PE20181956A1 (es) | 2018-12-17 |
DOP2018000128A (es) | 2018-09-30 |
JP7256011B2 (ja) | 2023-04-11 |
BR112018010802A2 (pt) | 2018-11-27 |
CA3006398A1 (fr) | 2017-06-01 |
SG11201803976VA (en) | 2018-06-28 |
MX2018006377A (es) | 2018-09-05 |
IL259249A (en) | 2018-07-31 |
EP3380517B1 (fr) | 2021-08-04 |
SG10201913503VA (en) | 2020-03-30 |
CN108473561A (zh) | 2018-08-31 |
RU2018122255A (ru) | 2019-12-19 |
TN2018000180A1 (en) | 2019-10-04 |
PH12018501114A1 (en) | 2019-01-28 |
KR20180080337A (ko) | 2018-07-11 |
EP3380517A1 (fr) | 2018-10-03 |
AU2016360987A1 (en) | 2018-06-07 |
CL2018001400A1 (es) | 2018-10-26 |
CN108473561B (zh) | 2022-12-16 |
CO2018005921A2 (es) | 2018-06-20 |
US11248055B2 (en) | 2022-02-15 |
RU2018122255A3 (fr) | 2020-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201802261B (en) | Polypeptides | |
IL255767A (en) | New polypeptides | |
HK1250041A1 (zh) | 多肽 | |
DK3072835T3 (da) | Fremgangsmåde til fremføring | |
DK3386954T3 (da) | Dimere kontrastmidler | |
DK3125898T3 (da) | Farmakofor til trail-induktion | |
ZA201704366B (en) | Il-17a-binding polypeptides | |
HK1250040A1 (zh) | 多肽 | |
MA43302A (fr) | Polypeptides inhibant le ligand cd40l | |
GB201515745D0 (en) | Proteins | |
GB201511787D0 (en) | Proteins | |
ZA201701348B (en) | New polypeptides | |
DE112015006829A5 (de) | Ventileinrichtung | |
GB201513033D0 (en) | Proteins | |
ZA201701071B (en) | Modified vip3 polypeptides | |
DK3359183T3 (da) | Polyepitop-konstrukter til anvendelse i immunoterapy | |
ES2775740T8 (es) | Péptidos | |
ITUA20162111A1 (it) | Mobile per cucine | |
ITUA20162109A1 (it) | Mobile per cucine | |
GB201611753D0 (en) | Methods for characterizing polypeptides | |
UA31448S (uk) | Упаковка-етикетка для кави | |
GB201515744D0 (en) | Proteins | |
GB201515245D0 (en) | Novel polypeptides | |
GB201502178D0 (en) | Detecting polypeptides | |
GB201503778D0 (en) | Proteins |